An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

This is a randomized (study medication assigned by chance), double-blind (neither the
Physician nor the participant know about the study medication), placebo-controlled (an
inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical
trial with a drug to test if the drug has a real effect), parallel-group (a medical research
study comparing the response in 2 or more groups of participants receiving different
interventions [treatments]) study to evaluate an appropriate intravenous (through a vein in
the arm) golimumab induction dose and to demonstrate the safety and efficacy of intravenous
induction dosing with golimumab in participants with moderately to severely active UC. At
Week 6, participants will be asked to participate in an additional 1-year maintenance study.
Participants not entering the 1-year golimumab maintenance study will be evaluated for safety
at Week 16. The duration of study will be 6 weeks for participants who enter the 1-year
golimumab maintenance study and 16 weeks for participant who do not enter the 1-year
golimumab maintenance study.There are 2 parts in this study. Part 1 is Phase 2 "dose-ranging"
portion of study. Participants enrolled in Part 1, will receive a single intravenous infusion
of either matching placebo for golimumab or 1 milligram (mg) per kilogram(kg), 2 mg per kg or
4 mg per kg of golimumab. Part 2 of the study is called "dose-confirming" and newly enrolled
participants will receive same doses studied in Part 1, until the doses for Part 2 are
selected and Phase 3 begins. At the time that the final doses are selected, all newly
enrolled participants will receive 1 of the selected doses or matching placebo; this is the
start of the Phase 3 portion of the study. Participants will primarily be assessed using Mayo
Score (it is a score developed for measuring disease activity). Participants' safety and
quality of life will also be monitored throughout the study.

Inclusion Criteria:

- Participants diagnosed with moderately to severely active ulcerative colitis (UC)
defined by a Mayo score of 6 to 12 inclusive at Baseline (Week 0), including an
endoscopic (examination of an internal part of the body with a lighted tube; looking
at a part of the body with a lighted tube) subscore of greater than or equal to 2

- Participants must have biopsy results (collected at the screening endoscopy (procedure
or obtained within the last year) consistent with the diagnosis of UC

- Participants either currently receiving treatment with, or have a history of failure
to respond to, or tolerate, at least 1 of the following therapies: oral
5-aminosalicylate (5-ASAs), oral corticosteroids, 6-mercaptopurine (6-MP) and
azathioprine (AZA)

- Participants with current dependency or with a history of corticosteroid dependency
(i.e. an inability to successfully taper corticosteroids without a return of the
symptoms of UC) - Not have a diagnosis of active TB

Exclusion Criteria:

- Participants with previous exposure to biologic anti-tumor necrosis factor (TNF)
agents

- Participants with severe extensive UC that is likely to require a colectomy (surgery
to remove part or all of the colon) within 12 weeks of study entry

- Participants having UC limited to the rectum only or to less than 20 centimeter (cm)
of the colon

- Presence of a stoma (an artificial permanent opening especially in the abdominal wall
made in surgical procedures) or presence of a fistula

- Participants with a history of extensive colonic resection